by Clinical Neuropsychologist | Friday, October 4, 2024 | Dementia
Abstract INTRODUCTION A recently developed mild behavioral impairment (MBI) diagnostic framework standardizes the early characterization of neuropsychiatric symptoms in older adults. However, the joint contributions of Alzheimer’s disease (AD) pathology and...
by Clinical Neuropsychologist | Wednesday, October 2, 2024 | Dementia
Abstract Introduction Transposable element (TE) dysregulation is associated with neuroinflammation in Alzheimer’s disease (AD) brains. Yet, TE quantitative trait loci (teQTL) have not been well characterized in human aged brains with AD. Methods We leveraged...
by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Limbic-predominant age-related TAR DNA-binding protein of 43 kDa encephalopathy neuropathologic change (LATE-NC) staging criteria were updated in 2023. We evaluated this updated staging using National Alzheimer’s Coordinating Center data....
by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract Introduction The angiotensin-converting enzyme 2 (ACE2), which is expressed in cerebral vascular endothelial cells (CVECs), has been currently identified as a functional receptor for SARS-CoV-2. Methods We specifically induced injury to ACE2-expressing CVECs...
by Clinical Neuropsychologist | Tuesday, October 1, 2024 | Dementia
Abstract INTRODUCTION Biomarkers for Alzheimer’s disease neuropathologic change (ADNC) have been instrumental in developing effective disease-modifying therapeutics. However, to prevent/treat dementia effectively, we require biomarkers for non-AD...